Carolyn Bertozzi

Carolyn R.
Bertozzi is the founder of Redwood Bioscience, Inc. (founded 2008).
Dr. Bertozzi is the founder of TwoStep Therapeutics, Inc. (founded 2024).
Dr. Bertozzi is the founder of Palleon Pharmaceuticals, Inc. (founded 2015).
Dr. Bertozzi is the founder of Venn Biosciences Corp.
(founded 2017).
Dr. Bertozzi is the founder of Lycia Therapeutics, Inc. (founded 2019).
Dr. Bertozzi is the founder of Valora Therapeutics, Inc. (founded 2023).
Dr. Bertozzi was the founder of Enable Biosciences, Inc. (founded 2016), serving as Chairman.
Dr. Bertozzi is also the founder of Firefly Bio, Inc...
Current positions include Director at Grace Science Foundation, Independent Director at OmniAb Operations, Inc., Independent Director at OmniAb, Inc. since 2022, Director at Stanford Chem-H since 2021, Director at Xaira Therapeutics, Inc., Independent Director at Eli Lilly & Co. starting 2025, Professor at Stanford University, Member of the American Chemical Society, Member of The Royal Society, Professor at Howard Hughes Medical Institute, Inc., Member of the National Academy of Medicine (United States), Member of the National Academy of Sciences, Member of the American Academy of Arts & Sciences, Member of the American Society for Biochemistry & Molecular Biology, Inc., Member of Accademia Nazionale dei Lincei, and Member of the National Academy of Inventors.
Former positions include Independent Director at Eli Lilly & Co. from 2017 to 2021, Director-Molecular Foundry at Lawrence Berkeley National Laboratory, Director at The Broad Institute, Inc., Director at Catalent, Inc., Director at Molecular Foundry, Independent Director at Alnylam Pharmaceuticals, Inc. from 2023 to 2025, and Professor at the University of California, Berkeley from 1996 to 2015.
Education includes undergraduate degree from Harvard University conferred in 1988 and doctorate from the University of California, Berkeley conferred in 1993.